Screening & Prevention — MCQs
On this page
A 65-year-old man attends his first NHS abdominal aortic aneurysm (AAA) screening appointment. The ultrasound shows an aortic diameter of 2.8 cm. He is asymptomatic and has well-controlled hypertension. He asks what happens next. What is the most appropriate management?
A 67-year-old man with COPD (FEV1 55% predicted) attends for review. He continues to smoke 10 cigarettes daily despite previous cessation advice. His BMI is 24 kg/m². He lives alone and manages his activities of daily living independently. He has had one exacerbation requiring oral antibiotics in the past year. His exercise tolerance is limited to 100 meters on the flat. Regarding pulmonary rehabilitation, which statement best represents the evidence for this intervention in his management?
A 35-year-old asymptomatic woman attends requesting cervical screening. She has never had cervical screening before. She has been sexually active since age 19 with 4 lifetime partners. She completed the HPV vaccination course at age 14. On checking the system, she has not responded to previous screening invitations. What is the most appropriate advice regarding her screening?
A 48-year-old woman who smokes 25 cigarettes daily attends for smoking cessation support. She has tried to quit three times previously using nicotine replacement therapy (NRT) patches with short-term success only. She is motivated to quit and has set a quit date in 2 weeks. She has no contraindications to pharmacotherapy. Which approach is most likely to result in successful long-term smoking cessation?
A 55-year-old man with type 2 diabetes attends for diabetic retinopathy screening. The screening report indicates background diabetic retinopathy (R1) in both eyes with referrable maculopathy (M1). His visual acuity is normal at 6/6 bilaterally and he has no visual symptoms. His HbA1c is 64 mmol/mol and blood pressure 136/84 mmHg. What is the most appropriate management of his screening result?
A 42-year-old woman with a family history of breast cancer asks about genetic testing. Her mother was diagnosed with breast cancer at age 38, and her maternal aunt at age 45. Both are alive and well after treatment. The patient is asymptomatic with no breast concerns. Using the National Institute for Health and Care Excellence (NICE) familial breast cancer guidelines, what is the most appropriate initial action?
A 32-year-old man presents with concerns about his alcohol consumption. He drinks approximately 45 units per week, predominantly on Friday and Saturday evenings. He works full-time and has not experienced any alcohol-related health problems or social consequences. His liver function tests are normal. He is motivated to reduce his intake. Which brief intervention approach is most evidence-based for this patient?
A 58-year-old woman attends her first invitation for breast screening. She is anxious after reading about overdiagnosis and questions the benefit of mammography. She has no breast symptoms and no family history of breast or ovarian cancer. Her mother had breast cancer diagnosed at age 72. Which statement most accurately represents the current evidence for breast screening in her age group?
A 45-year-old woman with a BMI of 33 kg/m² attends for weight management advice. She has tried multiple diets without sustained success. She has no other comorbidities. Her blood pressure is 128/82 mmHg, fasting glucose 5.2 mmol/L, and lipid profile is normal. She walks 30 minutes three times weekly. What is the minimum initial weight loss target you should discuss with her?
A 28-year-old pregnant woman at 11 weeks gestation attends for her booking appointment. She declines the combined screening test for Down syndrome (nuchal translucency and serum markers). She asks about other screening options available. Which single test should be offered as an alternative?
Screening & Prevention UK Medical PG Practice Questions and MCQs
Question 141: A 65-year-old man attends his first NHS abdominal aortic aneurysm (AAA) screening appointment. The ultrasound shows an aortic diameter of 2.8 cm. He is asymptomatic and has well-controlled hypertension. He asks what happens next. What is the most appropriate management?
- A. Discharge from screening programme with no further follow-up required
- B. Repeat ultrasound in 3 months
- C. Repeat ultrasound in 12 months (Correct Answer)
- D. Refer to vascular surgery for consideration of elective repair
- E. Arrange CT angiography for further assessment
Explanation: ***Repeat ultrasound in 12 months*** - In the **NHS AAA screening programme**, an aortic diameter between **2.5 cm and 2.9 cm** requires annual surveillance; similarly, aneurysms between 3.0 cm and 4.4 cm also warrant **yearly monitoring**. - This patient's measurement of **2.8 cm** falls into the category of a **small AAA**, necessitating annual follow-up to monitor for any expansion. *Discharge from screening programme with no further follow-up required* - Discharge from the screening programme is only appropriate if the aortic diameter is **less than 2.5 cm**, indicating a normal, non-aneurysmal aorta. - A 2.8 cm measurement is considered a **small aneurysm**, requiring ongoing surveillance due to the potential for growth and future complications. *Repeat ultrasound in 3 months* - **Three-monthly surveillance** is reserved for **medium-sized AAAs**, which are typically defined as having a diameter between **4.5 cm and 5.4 cm**. - A 2.8 cm aorta has a very low risk of rapid expansion or rupture, making such frequent monitoring unnecessary and outside standard guidelines. *Refer to vascular surgery for consideration of elective repair* - **Elective repair** or referral to vascular surgery is generally indicated when the aortic diameter reaches **5.5 cm or greater**. - For a 2.8 cm aneurysm, the risk of rupture is minimal, and surgical intervention is not currently warranted. *Arrange CT angiography for further assessment* - **CT angiography** is typically reserved for **pre-operative planning** for larger aneurysms or in cases where ultrasound is inconclusive, rather than for routine surveillance of small AAAs. - **Ultrasound** is the standard, safe, and cost-effective method for initial screening and ongoing surveillance of abdominal aortic aneurysms.
Question 142: A 67-year-old man with COPD (FEV1 55% predicted) attends for review. He continues to smoke 10 cigarettes daily despite previous cessation advice. His BMI is 24 kg/m². He lives alone and manages his activities of daily living independently. He has had one exacerbation requiring oral antibiotics in the past year. His exercise tolerance is limited to 100 meters on the flat. Regarding pulmonary rehabilitation, which statement best represents the evidence for this intervention in his management?
- A. Pulmonary rehabilitation improves exercise capacity and quality of life but has no effect on exacerbation rates or mortality
- B. Pulmonary rehabilitation should only be offered after smoking cessation is achieved
- C. Pulmonary rehabilitation improves exercise capacity, quality of life, and reduces hospital admissions in those with MRC grade 3-5 breathlessness (Correct Answer)
- D. Pulmonary rehabilitation is most effective when combined with long-term oxygen therapy
- E. Pulmonary rehabilitation is contraindicated in those with FEV1 >50% predicted
Explanation: ***Pulmonary rehabilitation improves exercise capacity, quality of life, and reduces hospital admissions in those with MRC grade 3-5 breathlessness*** - Pulmonary rehabilitation is a comprehensive intervention involving **exercise training** and **education** that significantly reduces **hospital admissions** and improves **health-related quality of life** in COPD patients. - This patient, with exercise tolerance limited to **100 meters** on the flat, likely falls into **MRC grade 3-4 breathlessness**, making him an ideal candidate for rehabilitation as per guidelines. *Pulmonary rehabilitation improves exercise capacity and quality of life but has no effect on exacerbation rates or mortality* - While its effect on **long-term mortality** is debated, strong evidence supports that pulmonary rehabilitation significantly reduces the frequency and severity of **COPD exacerbations** and subsequent hospitalizations. - It helps break the **cycle of inactivity** and deconditioning, which indirectly lessens the impact and improves recovery from future exacerbations. *Pulmonary rehabilitation should only be offered after smoking cessation is achieved* - **Smoking cessation** is crucial for slowing disease progression in COPD, but it is **not a prerequisite** for initiating pulmonary rehabilitation. - Rehabilitation focuses on improving **functional capacity** and **symptom management**, and its benefits are independent of a patient's current smoking status. *Pulmonary rehabilitation is most effective when combined with long-term oxygen therapy* - **Long-term oxygen therapy (LTOT)** is indicated for patients with **chronic hypoxemia** (PaO2 < 8 kPa or < 6.7 kPa with cor pulmonale) to improve survival, not as a standard adjunct to enhance pulmonary rehabilitation. - The benefits of pulmonary rehabilitation on **exercise tolerance** and **quality of life** are well-established, regardless of the patient's need for supplemental oxygen. *Pulmonary rehabilitation is contraindicated in those with FEV1 >50% predicted* - Referral criteria for pulmonary rehabilitation are primarily based on **functional impairment** and **symptom burden**, specifically **dyspnea** (e.g., MRC grade ≥3), rather than a specific FEV1 threshold. - Patients with **moderate airflow obstruction** (FEV1 50-80% predicted) can still experience significant improvements in exercise capacity and quality of life from rehabilitation if they are symptomatic.
Question 143: A 35-year-old asymptomatic woman attends requesting cervical screening. She has never had cervical screening before. She has been sexually active since age 19 with 4 lifetime partners. She completed the HPV vaccination course at age 14. On checking the system, she has not responded to previous screening invitations. What is the most appropriate advice regarding her screening?
- A. She does not require screening as she received HPV vaccination
- B. Perform cervical screening now as she is overdue (Correct Answer)
- C. Advise screening is only required from age 40 for vaccinated women
- D. Recommend starting screening at age 50 given her vaccination status
- E. Explain that screening could have been deferred to age 30 but should now commence
Explanation: ***Perform cervical screening now as she is overdue*** - In the UK, **cervical screening** begins at **age 25** for sexually active women; as this patient is 35 and has never been screened, she is significantly overdue. - Her prior **HPV vaccination** does not alter the requirement for routine screening, as it does not protect against all high-risk HPV strains. *She does not require screening as she received HPV vaccination* - The **HPV vaccine** offers protection against the most common high-risk HPV types but does not cover all strains that can cause cervical cancer. - Therefore, all vaccinated women must still adhere to standard **cervical screening** guidelines to detect any potential abnormalities. *Advise screening is only required from age 40 for vaccinated women* - There are no current national guidelines that recommend initiating **cervical screening** at age 40 for vaccinated women. - Delaying screening to this age would miss the critical period between **ages 25-39** when pre-cancerous lesions are most frequently detected. *Recommend starting screening at age 50 given her vaccination status* - Starting **cervical screening** at age 50 is significantly beyond the recommended initiation age and would lead to a substantial delay in detecting potential cervical pathologies. - **Vaccination status** does not justify such a late start, as early detection through screening is crucial regardless of vaccination. *Explain that screening could have been deferred to age 30 but should now commence* - Current UK national guidelines specify that **cervical screening** commences at **age 25**, not age 30, for all eligible women. - Regardless of any hypothetical deferrals, the patient is currently **35 years old** and has never been screened, making immediate action necessary.
Question 144: A 48-year-old woman who smokes 25 cigarettes daily attends for smoking cessation support. She has tried to quit three times previously using nicotine replacement therapy (NRT) patches with short-term success only. She is motivated to quit and has set a quit date in 2 weeks. She has no contraindications to pharmacotherapy. Which approach is most likely to result in successful long-term smoking cessation?
- A. Varenicline plus behavioural support (Correct Answer)
- B. Nicotine replacement therapy patches plus behavioural support
- C. Bupropion plus behavioural support
- D. Behavioural support alone with no pharmacotherapy
- E. Combination NRT (patch plus short-acting NRT) plus behavioural support
Explanation: ***Varenicline plus behavioural support*** - **Varenicline** is a **partial agonist** at the **α4β2 nicotinic acetylcholine receptors**, providing the highest long-term quit rates compared to other monotherapies. - Clinical guidelines recommend this approach as a **first-line therapy**, especially when previous attempts with single forms of **Nicotine Replacement Therapy (NRT)** have failed. *Nicotine replacement therapy patches plus behavioural support* - The patient has already failed to quit three times using **NRT patches**, demonstrating that this **monotherapy** is insufficient for her level of dependence. - While effective compared to placebo, single-form NRT is clinically **less effective** than varenicline or combination NRT strategies. *Bupropion plus behavioural support* - **Bupropion** is an antidepressant that doubles the chances of quitting, but head-to-head trials show it is **inferior to varenicline**. - It is a suitable alternative but typically reserved for patients who have **contraindications** or a preference against varenicline. *Behavioural support alone with no pharmacotherapy* - While **behavioural support** is a vital component of cessation, it has significantly **lower success rates** when used without pharmacological assistance in heavy smokers. - Pharmacotherapy is essential here to manage physical **withdrawal symptoms** and the neurobiological reward associated with smoking 25 cigarettes daily. *Combination NRT (patch plus short-acting NRT) plus behavioural support* - **Combination NRT** (e.g., patch plus gum) is more effective than single NRT, but meta-analyses generally place **varenicline** as the most potent option for long-term success. - It is a viable alternative, but given the patient's history and lack of contraindications, **varenicline** remains the preferred evidence-based recommendation.
Question 145: A 55-year-old man with type 2 diabetes attends for diabetic retinopathy screening. The screening report indicates background diabetic retinopathy (R1) in both eyes with referrable maculopathy (M1). His visual acuity is normal at 6/6 bilaterally and he has no visual symptoms. His HbA1c is 64 mmol/mol and blood pressure 136/84 mmHg. What is the most appropriate management of his screening result?
- A. Routine annual diabetic eye screening
- B. Refer to ophthalmology for assessment within 6 weeks (Correct Answer)
- C. Refer to ophthalmology for urgent assessment within 1 week
- D. Increase screening frequency to 6-monthly
- E. Optimize glycaemic and blood pressure control then repeat screening in 3 months
Explanation: ***Refer to ophthalmology for assessment within 6 weeks*** - The presence of **referrable maculopathy (M1)** necessitates a referral to an ophthalmology department even if the patient's **visual acuity** is currently normal (6/6). - Under standard screening guidelines, M1 indicates significant features like **exudates or thickening** near the fovea, requiring specialist assessment within a **6-week timeframe**. *Routine annual diabetic eye screening* - This is inappropriate because the patient has graduated from R0/R1 (no/background retinopathy only) to **M1 (referrable maculopathy)**, which requires intervention or closer monitoring. - Continuing **annual screening** would risk missing the window for potential treatment to prevent permanent vision loss. *Refer to ophthalmology for urgent assessment within 1 week* - **Urgent 1-week referrals** are generally reserved for **proliferative retinopathy (R3a)**, vitreous hemorrhage, or sudden vision loss. - While **M1** is serious, it is typically managed as a **prompt/routine referral** rather than an immediate ophthalmic emergency. *Increase screening frequency to 6-monthly* - **6-monthly screening** is often used for patients with **R2 (pre-proliferative)** changes that do not yet meet referral criteria. - Once a patient is graded as **M1**, they must be bridged from the screening program to **direct ophthalmology care** for detailed assessment like OCT. *Optimize glycaemic and blood pressure control then repeat screening in 3 months* - While **HbA1c optimization** (current 64 mmol/mol) and BP control are vital for slowing progression, they do not replace the need for **specialist referral** once M1 is detected. - Delaying clinical assessment for **3 months** while waiting for metabolic changes is non-compliant with safety guidelines for **maculopathy**.
Question 146: A 42-year-old woman with a family history of breast cancer asks about genetic testing. Her mother was diagnosed with breast cancer at age 38, and her maternal aunt at age 45. Both are alive and well after treatment. The patient is asymptomatic with no breast concerns. Using the National Institute for Health and Care Excellence (NICE) familial breast cancer guidelines, what is the most appropriate initial action?
- A. Refer directly to clinical genetics service
- B. Arrange bilateral mammography
- C. Calculate her lifetime risk and refer to family history clinic if >17% at age 40 (Correct Answer)
- D. Reassure as she does not meet referral criteria
- E. Offer prophylactic tamoxifen therapy
Explanation: ***Calculate her lifetime risk and refer to family history clinic if >17% at age 40*** - According to **NICE guidelines (CG164)**, the primary care management for asymptomatic women with a family history involves a formal **risk assessment** using validated tools like **IBIS** or **BOADICEA**. - A **lifetime risk of 17% to 30%** (moderate risk) or above justifies referral to a **specialist family history clinic** for further evaluation and management. *Refer directly to clinical genetics service* - This action is premature; patients should typically be assessed in a **specialist breast family history clinic** first to determine if they meet the threshold for genetic testing. - Referral to clinical genetics is usually reserved for those with a high probability (often **>10%**) of carrying a **pathogenic mutation** like BRCA1 or BRCA2. *Arrange bilateral mammography* - Routine **mammography** in primary care is not indicated for asymptomatic women under the age of 50 unless they are part of a specific **specialist surveillance program**. - The sensitivity of mammography is reduced in younger women due to **increased breast density**, making it an inappropriate first-line tool in this context. *Reassure as she does not meet referral criteria* - Simple reassurance is incorrect because two relatives diagnosed under age 50 constitutes a **moderate family history**, requiring formal risk calculation. - Ignoring this history would miss the opportunity for **enhanced surveillance** or chemoprevention if her calculated risk is indeed elevated. *Offer prophylactic tamoxifen therapy* - While **tamoxifen** can be used for breast cancer risk reduction, it is initiated by **specialists** in a secondary or tertiary care setting after a thorough risk-benefit discussion. - Primary care clinicians do not initiate **chemoprevention**; their role is to identify and refer patients who may benefit from it based on their **lifetime risk score**.
Question 147: A 32-year-old man presents with concerns about his alcohol consumption. He drinks approximately 45 units per week, predominantly on Friday and Saturday evenings. He works full-time and has not experienced any alcohol-related health problems or social consequences. His liver function tests are normal. He is motivated to reduce his intake. Which brief intervention approach is most evidence-based for this patient?
- A. Advise immediate abstinence and refer to specialist alcohol services
- B. Use FRAMES approach: Feedback, Responsibility, Advice, Menu of options, Empathy, Self-efficacy (Correct Answer)
- C. Prescribe naltrexone to reduce cravings
- D. Arrange weekly follow-up appointments for the next 3 months
- E. Refer to Alcoholics Anonymous
Explanation: ***Use FRAMES approach: Feedback, Responsibility, Advice, Menu of options, Empathy, Self-efficacy***- The **FRAMES approach** is an evidence-based brief intervention for patients with **hazardous drinking** who are motivated to reduce their intake, fitting this patient's profile (45 units/week without dependence or severe consequences).- It empowers the patient by providing **feedback** on risks, emphasizing **responsibility**, offering **advice** and a **menu of options**, showing **empathy**, and building **self-efficacy**, leading to sustained reductions in alcohol consumption.*Advise immediate abstinence and refer to specialist alcohol services*- **Immediate abstinence** and **specialist referrals** are generally reserved for patients with **alcohol dependence**, significant withdrawal risk, or severe alcohol-related health/social problems, which are not present here.- This approach is often too intensive for an individual with **hazardous drinking** who is motivated to reduce, rather than stop, alcohol intake completely.*Prescribe naltrexone to reduce cravings*- **Naltrexone** is a medication primarily indicated for treating **alcohol dependence** by reducing cravings and the pleasurable effects of alcohol, usually as part of a comprehensive treatment plan.- This patient presents as a **hazardous drinker** without evidence of dependence or severe cravings, making pharmacological intervention premature at this stage.*Arrange weekly follow-up appointments for the next 3 months*- While follow-up is beneficial, **weekly appointments** for three months represent an intensive level of care, which may be excessive for a patient with **hazardous drinking** and no immediate complications.- **Brief interventions** typically involve fewer, focused sessions, and a less intensive follow-up schedule might be more appropriate initially, escalating if needed.*Refer to Alcoholics Anonymous*- **Alcoholics Anonymous (AA)** is a self-help group primarily for individuals with **alcohol dependence** who are seeking to achieve and maintain abstinence.- This patient is motivated to **reduce** his intake and does not present with features of dependence that would necessitate referral to AA at this initial assessment.
Question 148: A 58-year-old woman attends her first invitation for breast screening. She is anxious after reading about overdiagnosis and questions the benefit of mammography. She has no breast symptoms and no family history of breast or ovarian cancer. Her mother had breast cancer diagnosed at age 72. Which statement most accurately represents the current evidence for breast screening in her age group?
- A. Screening reduces breast cancer mortality by approximately 20% but may lead to overdiagnosis in 10-15% of screen-detected cancers (Correct Answer)
- B. Screening reduces breast cancer mortality by approximately 50% with minimal overdiagnosis
- C. Screening has no proven mortality benefit but improves quality of life through early detection
- D. Screening reduces breast cancer mortality by approximately 40% but 30% of screen-detected cancers represent overdiagnosis
- E. Screening reduces all-cause mortality by approximately 20% in women aged 50-70
Explanation: ***Screening reduces breast cancer mortality by approximately 20% but may lead to overdiagnosis in 10-15% of screen-detected cancers*** - Current consensus and large meta-analyses demonstrate a **20% reduction in mortality** for women in the 50-70 age group through mammography. - **Overdiagnosis**, where a screen-detected cancer would never have caused clinical disease, is a recognized harm estimated at **10-15%** of cases. *Screening reduces breast cancer mortality by approximately 50% with minimal overdiagnosis* - A **50% mortality reduction** is an overestimation and does not reflect modern evidence or survival improvements from better treatment. - Claiming **minimal overdiagnosis** ignores significant clinical data regarding the detection of indolent lesions like DCIS. *Screening has no proven mortality benefit but improves quality of life through early detection* - Multiple randomized controlled trials have confirmed a **statistically significant breast cancer-specific mortality benefit** from screening. - Early detection often involves **anxiety and invasive procedures**, so quality of life is not always improved for those overdiagnosed. *Screening reduces breast cancer mortality by approximately 40% but 30% of screen-detected cancers represent overdiagnosis* - A **40% mortality reduction** is significantly higher than the evidence-based estimates used in the UK breast screening programme. - While some controversial studies suggest a **30% overdiagnosis rate**, the widely accepted figure for informed consent is closer to **10-15%**. *Screening reduces all-cause mortality by approximately 20% in women aged 50-70* - Screening reduces **disease-specific mortality** (breast cancer deaths) rather than **all-cause mortality**, which includes all other causes of death. - Because breast cancer accounts for only a fraction of total female deaths, the impact on **overall mortality** is not statistically observable in these trials.
Question 149: A 45-year-old woman with a BMI of 33 kg/m² attends for weight management advice. She has tried multiple diets without sustained success. She has no other comorbidities. Her blood pressure is 128/82 mmHg, fasting glucose 5.2 mmol/L, and lipid profile is normal. She walks 30 minutes three times weekly. What is the minimum initial weight loss target you should discuss with her?
- A. 2-3% of initial body weight
- B. 5-10% of initial body weight (Correct Answer)
- C. 10-15% of initial body weight
- D. 15-20% of initial body weight
- E. Achieve BMI <30 kg/m²
Explanation: ***5-10% of initial body weight***- This is the recommended **initial weight loss target** as it is achievable and produces **clinically significant health benefits**, including improvements in blood pressure, lipid profile, and glycemic control.- A **5-10% weight loss** can reduce the risk of progressing to type 2 diabetes and improve overall cardiovascular health. *2-3% of initial body weight*- A **2-3% weight loss** is often considered too modest to provide substantial and sustained **health benefits** in individuals with obesity.- While easier to achieve, it may not sufficiently impact associated comorbidities or significantly improve **metabolic markers**. *10-15% of initial body weight*- While a **10-15% weight loss** offers greater health benefits, setting it as an initial target can be **overly ambitious** for many patients.- Such aggressive initial goals can lead to **frustration** and reduce long-term adherence to weight management programs. *15-20% of initial body weight*- A **15-20% weight loss** is typically a goal for more intensive interventions like bariatric surgery or specialized medical weight loss programs.- It is generally **unrealistic** as an initial target for lifestyle changes and could be **demotivating** for patients. *Achieve BMI <30 kg/m²*- While a BMI below 30 kg/m² is a desirable outcome, directly aiming for a specific **BMI threshold** can be less effective as an initial target.- Percentage-based weight loss goals are often more **motivating** because they focus on achievable progress from the individual's starting point.
Question 150: A 28-year-old pregnant woman at 11 weeks gestation attends for her booking appointment. She declines the combined screening test for Down syndrome (nuchal translucency and serum markers). She asks about other screening options available. Which single test should be offered as an alternative?
- A. Cell-free fetal DNA testing
- B. Quadruple test at 16 weeks (Correct Answer)
- C. Non-invasive prenatal testing (NIPT)
- D. Amniocentesis at 15 weeks
- E. Detailed anomaly scan at 20 weeks
Explanation: ***Quadruple test at 16 weeks***- In the NHS Fetal Anomaly Screening Programme, the **quadruple test** is the standard alternative screening for women who decline or miss the **combined test window** (11+2 to 14+1 weeks).- It is performed between **15+0 and 20+0 weeks** and measures four biochemical markers: **AFP, hCG, uE3, and Inhibin-A**.*Cell-free fetal DNA testing*- While highly sensitive, **cell-free DNA** is not currently offered as a routine first-line screening option in the standard NHS pathway.- It is generally reserved as a secondary screening tool for women who receive a **high-risk result** from the combined or quadruple tests.*Non-invasive prenatal testing (NIPT)**- **NIPT** is functionally identical to cell-free DNA testing and is not the standard alternative to the booking screening in the public health protocol.- It serves as a more accurate screen to reduce the need for **invasive diagnostic procedures** but is not offered primary to all patients.*Amniocentesis at 15 weeks*- This is a **diagnostic test**, not a screening test, and is associated with a small **risk of miscarriage** (approximately 0.5-1%).- Diagnostic testing is only offered following a high-risk screening result or if there are specific known **genetic risks**.*Detailed anomaly scan at 20 weeks*- The **mid-pregnancy anomaly scan** is designed to identify structural abnormalities such as **spina bifida** or cardiac defects.- It is not an effective or primary screening tool for chromosomal conditions like **Down syndrome** (Trisomy 21).
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free